Search

Gary W Arendash

from Phoenix, AZ
Age ~75
Get Report
Also known as:
Gary Wayne Arendash, Gary P Arendash, Wayne G Arendash, Gary P Phillips, Wayne Arendash Gary
Phone and address:
13231 N 14Th Pl, Phoenix, AZ 85022
(602) 466-2179
Related to:
Janna L Huter, 53Emily Phillips, 31Jessica C Phillips, 34James C PhillipsGary P Phillips, 70Gary Phillips, 75Virginia L Phillips, 77Gary Phillips, 62Kathryn A Phillips, 65Marcia N Phillips
Connected to:
Sara B Arendell, 42Sean M Arendell, 39Stephanie A Arendell, 93Susan C Arendell, 68Darryl L Arender, 44Sheryl A Arender, 73Alex C Arends, 32Alexandra M Arends, 37Becky L Arends, 53Jennifer L Arends, 44

Gary Arendash Phones & Addresses

  • 13231 N 14Th Pl, Phoenix, AZ 85022 (602) 466-2179
  • Tampa, FL
  • 1670 Maddi Bella Cir, Prescott, AZ 86303 (928) 776-1092
  • 67360 Quijo Rd, Cathedral Cty, CA 92234 (760) 322-1725
  • 2405 Burlwood Dr, Lutz, FL 33549 (813) 949-8091
  • Riverside, CA
  • 1670 S Maddi Bella Cir, Prescott, AZ 86303 (813) 610-6306

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Resumes

Resumes

Gary Arendash Photo 1

Founder And Chief Research Officer

View page
Location:
Phoenix, AZ
Industry:
Medical Devices
Work:
Neuroem Therapeutics
Founder and Chief Research Officer
Education:
Universtiy of California, San Franciso Medical School
Doctorates, Doctor of Philosophy, Physiology, Neuroscience University of California, San Francisco - School of Medicine
Doctorates, Doctor of Philosophy, Physiology, Philosophy, Neuroscience Ucla Brain Research Institute
Gary Arendash Photo 2

Research Professor At University Of South Florida

View page
Location:
2 Tampa General Cir, Tampa, FL 33606
Industry:
Higher Education
Work:
University of South Florida
Research Professor
Skills:
Investment Banking
Gary Arendash Photo 3

Gary Arendash

View page
Location:
Phoenix, AZ

Business Records

Name / Title
Company / Classification
Phones & Addresses
Gary W. Arendash
Chairman, President
Neuroem Therapeutics, Inc
1670 S Maddi Bella Cir, Prescott, AZ 86303
Gary W Arendash
President/ceo
NEUROEM ALZHEIMER'S, INC
144 E Boca Raton Rd, Phoenix, AZ 85022
1209 Orange St, Wilmington, DE 19801

Publications

Us Patents

Transgenic Animal And Methods

View page
US Patent:
6781029, Aug 24, 2004
Filed:
Jul 13, 2001
Appl. No.:
09/903993
Inventors:
Lars Nilsson - Uppsala, SE
Huntington Potter - Tampa FL
Gary W. Arendash - Lutz FL
Assignee:
University of South Florida - Tampa FL
International Classification:
A01K 67027
US Classification:
800 14, 800 8, 800 12, 800 3, 435 4
Abstract:
A transgenic animal, preferably a mouse, that expresses human antichymotrypsin (ACT) in brain tissues is provided, together with animal tissue-derived cell lines and progeny animals of said transgenic animal. Progeny are obtained by mating the transgeny animal with select animal strains used as models of Alzheimers disease, related neurological disorders, or amyloidogenic diseases. Methods utilizing the parent and progeny animals and cells derived therefrom are disclosed for testing compounds for use as anti-inflammatory drugs, inhibitors of amyloidogenesis, and/or inhibitors of tau protein pathology associated with Alzheimers disease, in the treatment of a variety of neurological diseases.

Method Of Treating Cognitive Decline And Synaptic Loss Related To Alzheimer's Disease

View page
US Patent:
20090016995, Jan 15, 2009
Filed:
Nov 5, 2007
Appl. No.:
11/934940
Inventors:
Douglas W. Ethell - Riverside CA, US
Gary W. Arendash - Lutz FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 35/26
A61P 25/28
US Classification:
424 937
Abstract:
A method treating a subject with Alzheimer's disease wherein Aβ-reactive immune cells, splenocytes and lymphocytes, are generated in vitro or in vivo, re-stimulated in vitro, and then adoptively transferred into the cognitively-impaired subject. The population of immune cells can be derived from a donor with a natural or adaptive immune response to Aβ, stimulated by exposure to Aβ in vivo. The donor cells are then collected and re-stimulated by subsequent exposure to Aβ in vitro prior to administration to the subject. Alternatively, the population of immune cells can be derived from the subject and then stimulated by exposure to Aβ in vitro.

Methods Of Treating Cognitive Impairment

View page
US Patent:
20110142795, Jun 16, 2011
Filed:
Aug 4, 2009
Appl. No.:
13/057387
Inventors:
Huntington Potter - Tampa FL, US
Gary W. Arendash - Prescott AZ, US
Steven Bennett - Jupiter FL, US
Timothy Boyd - Seffner FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 38/20
A61K 31/7088
A61K 38/19
A61K 38/18
A61P 25/00
A61P 25/28
US Classification:
424 852, 514 44 R, 424 851, 514 77, 514 81, 514 86, 424 9467, 514 177, 514 178
Abstract:
The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

Materials And Methods For Preventing Or Treating Neurodegenerative Conditions Associated With Abeta Peptide Accumulation

View page
US Patent:
20110243957, Oct 6, 2011
Filed:
Sep 24, 2009
Appl. No.:
13/120633
Inventors:
Valentina Echeverria Moran - Largo FL, US
Gary W. Arendash - Prescott AZ, US
Assignee:
University of South Florida - Tampa FL
United States Department of Veterans Affairs - Washington DC
International Classification:
A61K 39/395
A61K 31/404
A61K 31/44
A61K 31/166
A61K 31/7088
A61K 38/17
A61P 25/28
C12N 5/0793
US Classification:
4241581, 514418, 514354, 514616, 514 44 A, 514 177, 435375
Abstract:
The subject invention concerns methods for preventing and/or treating neurodegenerative conditions associated with Abeta peptide accumulation in neural tissue in a human or animal. The subject invention also concerns methods for preventing or treating Alzheimer's disease-like neuropathology in a person or animal having trisomy 21 (Down's syndrome). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of a compound that inhibits function or activity of a Raf protein to a person or animal in need of treatment. In a specific embodiment, the Raf inhibitor is Sorafenib (NEXAVAR). Neurodegenerative conditions contemplated within the scope of the present invention include, for example, Alzheimer's disease and Parkinson's disease. The subject invention also concerns methods for preventing or inhibiting neuronal cell death and/or improving cell viability.

Methods Of Treating Cognitive Impairment

View page
US Patent:
20110311473, Dec 22, 2011
Filed:
Jun 21, 2011
Appl. No.:
13/165344
Inventors:
HUNTINGTON POTTER - Tampa FL, US
Gary W. Arendash - Prescott AZ, US
Steven Bennett - Jupiter FL, US
Timothy Boyd - Seffner FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - TAMPA FL
International Classification:
A61K 38/19
A61P 25/00
A61K 48/00
A61P 25/28
A61K 38/18
A61K 38/17
US Classification:
424 851, 514 77, 514 177, 514 44 R
Abstract:
The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

Prevention And Treatment Of Alzheimer's Disease Through Electromagnetic Field Exposure

View page
US Patent:
20120065456, Mar 15, 2012
Filed:
Sep 12, 2011
Appl. No.:
13/230415
Inventors:
Gary W. Arendash - Prescott AZ, US
Chuanhai Cao - Temple Terrace FL, US
Jun Tan - Tampa FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
A61N 2/02
US Classification:
600 13
Abstract:
The invention includes a method of treating and preventing a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule (preferably daily) for a predetermined treatment period.The predetermined frequency, according to a preferred embodiment, is about 918 MHz with a specific absorption rate (SAR) of about 0.25 W/kg+/−2 dB. The predetermined absorption period of this preferred embodiment is about one hour. The treatment period is long-term, being greater than about 6 months and preferably between about 7 and 9 months.

Vasoactive Effects And Free Radical Generation By .Beta.-Amyloid Peptides

View page
US Patent:
60110198, Jan 4, 2000
Filed:
Nov 12, 1996
Appl. No.:
8/747457
Inventors:
Thomas N. Thomas - Palm Harbor FL
Michael Mullan - Tampa FL
Gary W. Arendash - Lutz FL
Fiona C. Crawford - Tampa FL
Zhiming Suo - Tampa FL
Assignee:
University of South Florida - Tampa FL
International Classification:
A01N 4304
US Classification:
514 43
Abstract:
A method is disclosed for treating and preventing diseases, wherein at least one of the causes of the disease is. beta. -amyloid peptide induced change in free radical production resulting in vascular endothelial dysfunction and vasoactivity, by antagonizing vascular free radicals in excess of functional equilibrium. An animal model for the disease is also disclosed.

Increased Human Life Span And Health Span Through Transcranial Electromagnetic Treatment

View page
US Patent:
20230050752, Feb 16, 2023
Filed:
Oct 28, 2022
Appl. No.:
17/975820
Inventors:
- Phoenix AZ, US
Gary W. Arendash - Phoenix AZ, US
International Classification:
A61N 2/02
A61N 2/00
A61N 1/40
A61N 1/36
A61N 1/04
Abstract:
The present disclosure describes methods and devices for increasing human life span (longevity) via electromagnetic treatment. An array of electromagnetic emitters are positioned proximal to a subject. An electromagnetic wave generator generates electromagnetic fields having a predetermined set of parameters. Life span is increased by applying the electromagnetic waves to the subject through the electromagnetic emitters.
Control profile
Gary W Arendash from Phoenix, AZ, age ~75 Get Report